Cybin Inc. (OTCMKTS:CYBN - Get Free Report) shot up 0.2% on Tuesday . The company traded as high as $10.18 and last traded at $10.14. 57,400 shares traded hands during trading, a decline of 60% from the average session volume of 142,240 shares. The stock had previously closed at $10.12.
Cybin Stock Performance
The company has a fifty day simple moving average of $6.79 and a two-hundred day simple moving average of $2.59. The firm has a market capitalization of $198.72 million, a PE ratio of -1.64 and a beta of 0.38.
Cybin (OTCMKTS:CYBN - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.01) earnings per share for the quarter. On average, equities analysts anticipate that Cybin Inc. will post -0.19 earnings per share for the current fiscal year.
Cybin Company Profile
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Articles
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
